Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 15/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29923339 | 1.00 | GPR119 (0.37) | GPR119KDM4CKDM4DSCN5ASCN9A | |
| SCHEMBL29923313 | 0.92 | GPR119 (0.33) | GPR119KDM4CSCN5ASCN9A | |
| SCHEMBL27214554 | 0.91 | BRD4 (0.34) | GPR119KDM4CKDM4D | |
| SCHEMBL27214590 | 0.91 | BRD4 (0.34) | GPR119KDM4CKDM4D | |
| SCHEMBL27231219 | 0.91 | BRD4 (0.34) | GPR119KDM4CKDM4D | |
| SCHEMBL29923582 | 0.89 | GPR119 (0.35) | GPR119KDM4C | |
| SCHEMBL29923158 | 0.88 | SCN9A (0.34) | KDM4CSCN5ASCN9AHSD17B10 | |
| SCHEMBL29923235 | 0.87 | KDM4C (0.36) | GPR119KDM4CKDM6B | |
| SCHEMBL29923543 | 0.87 | KDM4C (0.34) | GPR119KDM4CKDM6BHSD17B10 | |
| SCHEMBL27231197 | 0.87 | KDM4C (0.34) | GPR119KDM4CKDM6BHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| WO-2022217232-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150330-A1 | CHROMANS AND BENZOFURANS AS 5-HT1A AND TAAR1 AGONISTS | TAAR1, HTR1A, HTR1F | GPR119 234/4885KDM4C 3293/4885KDM4D 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.